6
Sep
2023
Freeing the Biotech Founders: Zach Weinberg and Alexis Borisy on The Long Run
Today there are two guests on The Long Run: Zach Weinberg and Alexis Borisy. They are co-founders of Curie.Bio. Curie is a venture capital fund with $520 million, mostly for seed investments and Series A rounds in biotech startups. It also is also building up in-house R&D expertise which it uses to help the entrepreneurs it backs. Curie pitches itself... Read More
6
Feb
2017
A Canadian Biotech Breakaway?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Jun
2016
Going Public at Beaten Down Valuations? The Crossover Hangover
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Apr
2015
Which Big Public Investors Are ‘Crossing Over’ Into the Private Arena?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Mar
2015
The Top 20 Early-Stage Biotech Investors (And 2 Resuscitated By the Boom)
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Mar
2015
2015 Power Rankings: Biotech Investment Banks
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Feb
2015
Who Is Poised To Go Public in 2015, and Who Isn’t?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Feb
2015
Frazier, Versant Find an AFib Drug To Bet on at Laguna
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Feb
2015
The Merck Exodus: Where Are the Talented People Going?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Feb
2015
Implications of the Biotech Boom on the Business and Science of R&D
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.